Researchers at the University of Oxford in the UK have been awarded up to £600,000 ($786,525) from Cancer Research UK to create the world’s first vaccine to prevent ovarian cancer.

OvarianVax is a vaccine that will teach the immune system to recognise and attack the earliest stages of ovarian cancer.

There are around 7,500 new ovarian cancer cases every year in the UK, and it’s the sixth most common cancer in women.

Women with faulty BRCA1 genes have a higher ovarian cancer risk, and to a lesser extent in women with a faulty BRCA2 gene, versus women without these faulty variants.

Currently, some women with BRCA1/2 mutations are offered surgery which can help to prevent cancer, but can involve the removal of the ovaries and fallopian tubes.

“We need better strategies to prevent ovarian cancer,” said Professor Ahmed Ahmed, lead for the OvarianVax project. “OvarianVax could offer the solution to prevent cancer in women at high risk. Teaching the immune system to recognise the very early signs of cancer is a tough challenge. But we now have highly sophisticated tools, which give us real insights into how the immune system recognises ovarian cancer.”

Scientists will find out which proteins on the surface of early-stage ovarian cancer cells are recognised most by the immune system and how effective the vaccine is at killing organoids of ovarian cancer in the lab.

If this research is successful, the team will then begin working on clinical trials of the vaccine.

“Projects like OvarianVax are a really important step forward into an exciting future, where cancer is much more preventable. This funding will power crucial discoveries in the lab which will realise our ambitions to improve ovarian cancer survival,” said Michelle Mitchell, Chief Executive of Cancer Research UK.

Diana Spencer, Senior Digital Content Editor, DDW